Drugs / Dobutamine
Dobutamine
also known as
46236 · COMPOUND 81929 · Dl-dobutamine · Dl-dobutamine hydrochloride · Dobutamin · Dobutamina · Dobutamine hcl · Dobutamine Hydrochloride · +5 more
Small molecule targets ADRB1, ADRB2 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DOBUTREX | — | 1978-07-18 | fda.gov ↗ |
Trials 34
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06210217 | Feb → Mar 2024 | — | Sichuan University | Unknown | No outcome recorded |
| Phase 0 | NCT05241912 | Feb 2022 → Jun 2023 | — | Guangzhou Red Cross Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04249258 | Jan 2020 → Nov 2021 | cardiac rhythm disease | Northwell Health | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03098680 | Apr 2017 → Feb 2020 | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06878742 | Jun 2024 → Jun 2029 expected | — | Instituto de Investigación Hospital Universitario La Paz | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06318260 | Apr 2024 → Jul 2026 overdue | wild type ATTR amyloidosis | Steen Hvitfeldt Poulsen | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04020172 | Jul 2019 → May 2024 | — | Dr. Glenio Mizubuti (MD, PhD) | Completed | No outcome recorded |
| Phase 1/2 | NCT03311178 | May 2014 → Oct 2015 | — | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07406477 | Sep 2026 → Apr 2029 expected | brain hypoxia - ischemia | University of Alberta | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05953142 | Feb 2024 → Dec 2025 | infectious disease with sepsis, lactic acidosis | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT02019810 | Oct 2014 → Jun 2016 | brain injury | University Hospital, Grenoble | Unknown | No outcome recorded |
| Phase 2 | NCT01605279 | Sep 2010 → Oct 2012 | — | Adelina Pellicer | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT00093301 | Oct 2004 → Apr 2006 | cardiogenic shock, infectious disease with sepsis | Wentworth Area Health Services | Unknown | No outcome recorded |
| Phase 2/3 | NCT00148278 | Oct 1999 → Dec 2004 | infectious disease with sepsis | University of Versailles | Completed | Missed primary |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT04166331 | Sep 2020 → Jul 2025 | cardiomyopathy, infectious disease with sepsis, left ventricular failure | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 3 | NCT03340779 | Jan 2018 → Nov 2019 | cardiogenic shock | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 3 | NCT00348504 | Mar 2003 → Jun 2005 | heart failure | Abbott | Completed | Missed primary |
| Phase 48 trials · 1 missed | ||||||
| Phase 4 | NCT05025644 | Mar 2023 → Aug 2024 | hypertrophic cardiomyopathy | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT04893655 | Sep 2021 → Jul 2023 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT03846765 | Jul 2019 → May 2021 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT01930734 | Oct 2013 → Oct 2015 | heart failure | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01375335 | Jun 2011 → Aug 2013 | heart failure | University of Aarhus | Suspended | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01042873 | Jan 2010 → Dec 2020 | heart failure | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 4 | NCT01418118 | Oct 2008 → Feb 2010 | head and neck cancer, hypotensive disorder, oral cavity cancer | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT00484133 | Jun 2007 → Dec 2008 | infectious disease with sepsis | Onze Lieve Vrouwe Gasthuis | Unknown | Missed primary |
| Phase not applicable9 trials | ||||||
| — | NCT07000994 | Jun 2025 → Jan 2026 | postoperative ventricular dysfunction | University of Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT06462313 | Jun 2024 → Nov 2025 | infectious disease with sepsis | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| — | NCT05999487 | Oct 2023 → Mar 2024 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT05944146 | May 2023 → Dec 2026 expected | — | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| — | NCT05196815 | Jul 2022 → Mar 2024 | congenital anomaly of cardiovascular system | The Royal Wolverhampton Hospitals NHS Trust | Completed | No outcome recorded |
| — | NCT05797584 | Mar 2019 → Mar 2025 | heart failure | Istituto Auxologico Italiano | Unknown | No outcome recorded |
| — | NCT02559141 | Mar 2014 → Oct 2015 | — | University Hospital Schleswig-Holstein | Completed | No outcome recorded |
| — | NCT01354613 | Apr 2011 → Dec 2013 | diastolic heart failure, hypertensive heart disease, lung disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00100412 | Oct 1999 → Sep 2002 | myalgic encephalomeyelitis/chronic fatigue syndrome, persian gulf syndrome, post-traumatic stress disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Comparator or background therapy34 trials | ||||||
| Phase 0 | NCT00763035 Comparator | Jan 2009 → Dec 2010 | asthma, chronic obstructive pulmonary disease, intermediate coronary syndrome | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT00281255 Background | Jun 2003 → Jun 2013 | congestive heart failure, dilated cardiomyopathy | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 2 | NCT05350592 Comparator | Mar 2022 → Jun 2025 overdue | acute myocardial infarction, cardiogenic shock | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02644057 Comparator | Mar → Sep 2016 | cardio-renal syndrome | Maimonides Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01301313 Comparator | Feb 2011 → Feb 2012 | heart failure | Jose Luis Vazquez Martinez | Terminated | No outcome recorded |
| Phase 2 | NCT00624650 Comparator | Feb 2008 → Jan 2011 | acute lung injury | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT00800306 Comparator | Nov 2007 → Feb 2008 | infectious disease with sepsis | University of Roma La Sapienza | Completed | Met primary |
| Phase 2 | NCT00338455 Background | Sep 2006 → Oct 2007 | congestive heart failure, impaired renal function disease, kidney failure | Scios, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00953303 Comparator | Jan 2009 → Sep 2011 | heart failure | Hebei Medical University | Completed | No outcome recorded |
| Phase 3 | NCT04742764 Background | Jan 2024 → Oct 2026 | infectious disease with sepsis | University of Pecs | Suspended | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05594342 Background | Jul 2022 → Jan 2023 | cardiogenic shock, heart failure, ischemic disease | The Young Investigator Group of Cardiovascular Research | Unknown | No outcome recorded |
| Phase 3 | NCT02361801 Comparator | Feb 2015 → Feb 2016 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT02133105 Comparator | Apr 2014 → May 2017 | cardio-renal syndrome | Göteborg University | Completed | No outcome recorded |
| Phase 3 | NCT00564993 Comparator | Nov 2007 → May 2011 | tetralogy of fallot | Competence Network for Congenital Heart Defects | Terminated | No outcome recorded |
| Phase 4 | NCT07186062 Comparator | Jun 2022 → Jun 2024 | cardio-renal syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05267886 Comparator | Mar 2022 → Dec 2026 expected | cardiogenic shock | Ottawa Heart Institute Research Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT02767024 Comparator | May 2018 | symptomatic heart failure | Montefiore Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03207165 Comparator | Aug 2017 → Jun 2020 | acute coronary syndrome, cardiogenic shock, pulmonary edema | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02012946 Comparator | Dec 2013 | cardiovascular disorder | Azienda Policlinico Umberto I | Unknown | No outcome recorded |
| Phase 4 | NCT01427686 Comparator | Jun 2011 → Feb 2015 | hypotensive disorder | University of Ulm | Unknown | No outcome recorded |
| Phase 4 | NCT01969071 Comparator | Jul 2009 → Jan 2013 | mitral valve disorder | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00549419 Comparator | Oct 2007 → Jan 2009 | — | Klinikum Ludwigshafen | Completed | No outcome recorded |
| — | NCT06631482 Comparator | Sep 2024 → Oct 2025 overdue | orthostatic hypotension 2 | National Taiwan University Hospital | Active not recruiting | No outcome recorded |
| — | NCT05064202 Background | Oct 2023 → Oct 2027 expected | cardiogenic shock | Amsterdam UMC, location VUmc | Not yet recruiting | No outcome recorded |
| — | NCT05587400 Background | Jul 2022 → Dec 2024 | pulmonary arterial hypertension | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT04792424 Background | Apr 2021 → May 2022 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02730117 Background | Mar 2016 → Jul 2017 | acute kidney injury | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT02742974 Background | Oct 2015 → Nov 2017 | — | CAMC Health System | Terminated | No outcome recorded |
| — | NCT02505451 Background | Jul 2015 → Jan 2018 | — | University of Avignon | Completed | No outcome recorded |
| — | NCT03288051 Comparator | Apr 2014 → Feb 2017 | — | Szeged University | Completed | No outcome recorded |
| — | NCT02963454 Comparator | Jan 2011 → Feb 2018 | infectious disease with sepsis | Military Hospital of Tunis | Unknown | No outcome recorded |
| — | NCT01271153 Comparator | Aug 2010 → Jan 2013 | infectious disease with sepsis | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| — | NCT00998205 Background | Jun 2008 → Jan 2011 | diastolic heart failure | University of Missouri-Columbia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-12-05 | Upsher-Smith Laboratories | Regulatory MHLW Approves New Indication for RISEDRONATE Tablets and DOBUTAMINE I.V. Infusion upsher-smith.com ↗
This approval expands the indication of RISEDRONATE SODIUM Tablets 17.5 mg [SAWAI] and DOBUTAMINE HYDROCHLORIDE I.V. Infusion 100 mg [SAWAI] to include the same uses as their brand equivalents. |
| 2005-11-16 | Orion Corporation, Orion Pharma | Results Abbott reports levosimendan (Simdax®) results from large mortality trial in patients with acute decompensated heart failure orionpharma.com ↗
Although the study did not discern a difference in long-term outcome between levosimendan and dobutamine, earlier timepoints, closer to actual drug administration, appear to favor levosimendan. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-12-05 | Upsher-Smith Laboratories | MHLW Approves New Indication for RISEDRONATE Tablets and DOBUTAMINE I.V. Infusion upsher-smith.com ↗ |
| 2005-11-16 | Orion Corporation, Orion Pharma | Abbott reports levosimendan (Simdax®) results from large mortality trial in patients with acute decompensated heart failure orionpharma.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 69 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dobutamine | “Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.” NCT04742764 ↗67“Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension.” NCT06631482 ↗ “Protocol-directed inotropic support based on hemodynamic monitoring data. Agents included dobutamine and dopamine.” NCT02742974 ↗ “Dobutamine has a positive chronotropic effect that might cause higher myocardial oxygen consumption.” NCT03340779 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT02730117 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT04792424 ↗ “dopamine and / or dobutamine and / or milrinone and / or adrenaline” NCT01301313 ↗ “Furosemide; torsemide; nitroglycerin; dopamine; Dobutamine” NCT00953303 ↗ “Enoximone, Dobutamine, Dopamine, Milrinone” NCT05064202 ↗ “Dobutamine (Dobutrex®) infusion.” NCT06318260 ↗ “Dobutamine” NCT03340779 ↗ |
| Known as | 46236 | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | COMPOUND 81929 | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | Dl-dobutamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | Dl-dobutamine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | Dobutamin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00564993 ↗ |
| Known as | Dobutamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | Dobutamine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | Dobutamine Hydrochloride | “Pre and post-CPB Drug: Dobutamine Hydrochloride” NCT05025644 ↗ |
| Known as | Dobutrex | “Dobutamine (Dobutrex®) infusion.” NCT06318260 ↗ |
| Known as | Inotrex | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | NSC-299583 | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | Posiject | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Known as | Racemic dobutamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL926 ↗ |
| Action | Activate | “Dobutamine is beta-adrenergic agonist that stimulates myocardium to increase force of contraction and cardiac output.” NCT00100412 ↗ |
| Modality | Small molecule | “Phenylephrine and dobutamine are synthetic catecholamines, analogues of endogenous chemical messenger substances released by sympathetic nerve fibers and by adrenal medulla...” NCT00100412 ↗ |
| Route | Intravenous | “The hypotheses of target organ dysfunction are evaluated using graded intravenous infusions of two drugs, phenylephrine and dobutamine, and by measuring the resultant...” NCT00100412 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor agonist” CHEMBL926 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL926 ↗ |